NO20044498L - Kombinasjonsterapi for behandling av cancer - Google Patents

Kombinasjonsterapi for behandling av cancer

Info

Publication number
NO20044498L
NO20044498L NO20044498A NO20044498A NO20044498L NO 20044498 L NO20044498 L NO 20044498L NO 20044498 A NO20044498 A NO 20044498A NO 20044498 A NO20044498 A NO 20044498A NO 20044498 L NO20044498 L NO 20044498L
Authority
NO
Norway
Prior art keywords
cancer
treatment
effective amount
combination therapy
warm
Prior art date
Application number
NO20044498A
Other languages
English (en)
Norwegian (no)
Inventor
Ryan Anderson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208680A external-priority patent/GB0208680D0/en
Priority claimed from GB0218388A external-priority patent/GB0218388D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20044498L publication Critical patent/NO20044498L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20044498A 2002-04-16 2004-10-21 Kombinasjonsterapi for behandling av cancer NO20044498L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208680A GB0208680D0 (en) 2002-04-16 2002-04-16 Combination therapy
GB0218388A GB0218388D0 (en) 2002-08-08 2002-08-08 Combination therapy
PCT/GB2003/001617 WO2003088971A1 (en) 2002-04-16 2003-04-14 Combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20044498L true NO20044498L (no) 2004-11-04

Family

ID=29252451

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044498A NO20044498L (no) 2002-04-16 2004-10-21 Kombinasjonsterapi for behandling av cancer

Country Status (16)

Country Link
US (1) US20050215530A1 (enExample)
EP (1) EP1496909B1 (enExample)
JP (1) JP2005530735A (enExample)
KR (1) KR20040103964A (enExample)
CN (1) CN100352441C (enExample)
AT (1) ATE353650T1 (enExample)
AU (1) AU2003216558B2 (enExample)
BR (1) BR0309226A (enExample)
CA (1) CA2482591A1 (enExample)
DE (1) DE60311788T2 (enExample)
ES (1) ES2280735T3 (enExample)
IL (1) IL164564A0 (enExample)
MX (1) MXPA04010166A (enExample)
NO (1) NO20044498L (enExample)
NZ (1) NZ535739A (enExample)
WO (1) WO2003088971A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004112801A2 (en) * 2003-06-18 2004-12-29 Angiogene Pharmaceuticals Limited Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
AR046337A1 (es) * 2003-10-15 2005-12-07 Osi Pharm Inc Imidazopirazina inhibidoras de las tirosinquinasas
CN1960993A (zh) * 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
CA2569132A1 (en) * 2004-06-03 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
JP2005530735A (ja) 2005-10-13
BR0309226A (pt) 2005-02-09
EP1496909A1 (en) 2005-01-19
CN100352441C (zh) 2007-12-05
EP1496909B1 (en) 2007-02-14
NZ535739A (en) 2008-01-31
CN1658880A (zh) 2005-08-24
WO2003088971A1 (en) 2003-10-30
KR20040103964A (ko) 2004-12-09
CA2482591A1 (en) 2003-10-30
HK1071310A1 (en) 2005-07-15
ATE353650T1 (de) 2007-03-15
ES2280735T3 (es) 2007-09-16
AU2003216558B2 (en) 2008-05-29
IL164564A0 (en) 2005-12-18
AU2003216558A1 (en) 2003-11-03
US20050215530A1 (en) 2005-09-29
MXPA04010166A (es) 2005-02-03
DE60311788D1 (de) 2007-03-29
DE60311788T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064753L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
ATE339209T1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application